Co-transplantation of acellular allogeneic dermis and autologous split-thickness skin for repairing diabetic foot wound

doi:10.12307/2022.473

Abstract

Abstract: BACKGROUND: In recent years, the combined transplantation of acellular allogeneic dermis and autologous split-thickness skin has achieved good results in burn wound repair at functional sites; however, few reports have documented the application of this technology in the repair of diabetic foot wounds.
OBJECTIVE: To evaluate the clinical value of co-transplantation of acellular allogeneic dermis and autologous split-thickness skin in the repair of diabetic foot wound.
METHODS: A retrospective analysis was made on the clinical data of 52 patients with diabetic foot wound who were treated with co-transplantation of acellular allogeneic dermis and autologous split-thickness skin (experimental group, n=26) or with autologous split-thickness skin (control group, n=26) between May 2017 and April 2020. The number of postoperative wound infection, skin graft survival rate, reoperation rate, wound healing time and wound recurrence rate during the 1-year follow-up period were compared between the two groups. An approval was obtained from the Ethics Committee of Beijing Shijitan Hospital, Capital Medical University. Informed consent was obtained from all patients and their relatives.
RESULTS AND CONCLUSION: In the control group, eight patients developed infection in the skin graft area after operation, and among them, six patients had skin graft necrosis. After secondary operation, 2 out of the 6 patients healed after dressing treatment. In the experimental group, two patients developed infection after operation, and their wounds failed to be repaired but healed after dressing. The survival rate of skin graft in the experimental group (92.3%) was significantly higher than that in the control group (69.2%; P < 0.05). The reoperation rate of the experimental group was significantly lower than that of the control group (0 vs. 23.1%; P < 0.05). The wound healing time in the experimental group was (16.15±2.68) days, which was significantly shorter than that in the control group [(21.92±3.05) days; t=-7.25, P < 0.05]. The patients in both groups were followed up for 3 months to 1 year after operation. During the follow-up period, two patients in the experimental group and nine patients in the control group were re-hospitalized after wound recurrence. The wound recurrence rate in the experimental group was significantly lower than that in the control group (7.7% vs. 34.6%; P < 0.05). Therefore, compared with autologous split-thickness skin graft, the co-transplantation of acellular allogeneic dermis and autologous split-thickness skin can promote the survival of the skin and shorten the healing time of the wound. The repaired wound is friction-resistant, which reduces the recurrence of diabetic foot wound, even though there is an increase in hospital cost.

Key words: diabetic foot, acellular allogeneic dermis, autologous split-thickness skin graft, wound repair

CLC Number:

Gao Lei, Qin Xinyuan, Li Tianbo, Wang Shuo, Yu Zeyang, Wang Jiangning. Co-transplantation of acellular allogeneic dermis and autologous split-thickness skin for repairing diabetic foot wound[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(14): 2138-2143.

Figures/Tables 5

References

[1] LECHLEITNER M, ABRAHAMIAN H, FRANCESCONI C, et al. Diabetische Neuropathie und diabetischer Fuß (Update 2019) [Diabetic neuropathy and diabetic foot syndrome (Update 2019)]. Wien Klin Wochenschr. 2019;131(Suppl 1):141-150.
[2] YAZDANPANAH L, SHAHBAZIAN H, NAZARI I, et al. Incidence and Risk Factors of Diabetic Foot Ulcer: A Population-Based Diabetic Foot Cohort (ADFC Study)-Two-Year Follow-Up Study. Int J Endocrinol. 2018; 2018:7631659.
[3] 王江宁, 高磊.糖尿病足慢性创面治疗的新进展[J].中国修复重建外科杂志,2018,32(7):832-837
[4] ZELEN CM, ORGILL DP, SERENA TE, et al. An aseptically processed, acellular, reticular, allogenic human dermis improves healing in diabetic foot ulcers: A prospective, randomised, controlled, multicentre follow-up trial. Int Wound J. 2018;15(5):731-739.
[5] SARKOZYOVA N, DRAGUNOVA J, BUKOVCAN P, et al. Preparation and processing of human allogenic dermal matrix for utilization in reconstructive surgical procedures. Bratisl Lek Listy. 2020;121(6):386-394.
[6] 郭海雷,凌翔伟,刘政军,等.刃厚头皮与异体脱细胞真皮基质复合移植修复特大面积烧伤患者手部深度创面[J].中华烧伤杂志, 2019,35(12):876-878.
[7] WEAVER ML, HICKS CW, CANNER JK, et al. The Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification system predicts wound healing better than direct angiosome perfusion in diabetic foot wounds. J Vasc Surg. 2018;68(5):1473-1481.
[8] 柯昌能,刘坡,陈杰明,等.脱细胞同种异体真皮与自体刃厚皮复合移植烧伤功能部位修复创面[J].中国组织工程研究,2015, 19(29):4652-4656.
[9] BORDIANU A, BOBIRCĂ F, PĂTRAŞCU T. Skin Grafting in the Treatment of Diabetic Foot Soft Tissue Defects. Chirurgia (Bucur). 2018;113(5):644-650.
[10] 薛春利,胡志成,杨祖贤,等.异体脱细胞真皮基质治疗糖尿病足溃疡临床效果荟萃分析[J].中华烧伤杂志,2016,32(12):725-729.
[11] SANNIEC K, NGUYEN T, VAN ASTEN S,et al. Split-Thickness Skin Grafts to the Foot and Ankle of Diabetic Patients. J Am Podiatr Med Assoc. 2017;107(5):365-368.
[12] ZELEN CM, ORGILL DP, SERENA T, et al. A prospective, randomised, controlled, multicentre clinical trial examining healing rates, safety and cost to closure of an acellular reticular allogenic human dermis versus standard of care in the treatment of chronic diabetic foot ulcers. Int Wound J. 2017;14(2):307-315.
[13] CAMPITIELLO F, MANCONE M, DELLA CORTE A,et al. To evaluate the efficacy of an acellular flowable matrix in comparison with a wet dressing for the treatment of patients with diabetic foot ulcers: a randomized clinical trial. Updates Surg. 2017;69(4):523-529.
[14] WIDJAJA W, TAN J, MAITZ PKM. Efficacy of dermal substitute on deep dermal to full thickness burn injury: a systematic review. ANZ J Surg. 2017;87(6):446-452.
[15] PIRAYESH A, HOEKSEMA H, RICHTERS C, et al. Glyaderm(®) dermal substitute: clinical application and long-term results in 55 patients. Burns. 2015;41(1):132-144.
[16] BOHAC M, VARGA I, POLAK S, et al. Delayed post mastectomy breast reconstructions with allogeneic acellular dermal matrix prepared by a new decellularizationmethod. Cell Tissue Bank. 2018;19(1):61-68.
[17] SPECHT M, KELM S, MIRASTSCHIJSKI U. Eignung biologischer azellulärer dermaler Matrices als Hautersatz [Suitability of biological acellular dermal matrices as a skin replacement]. Handchir Mikrochir Plast Chir. 2020;52(6):533-544.
[18] GOODARZI P, FALAHZADEH K, NEMATIZADEH M, et al. Tissue Engineered Skin Substitutes. Adv Exp Med Biol. 2018;1107:143-188.
[19] NITA M, PLISZCZYŃSKI J, KOWALEWSKI C, et al. New Treatment of Wound Healing With Allogenic Acellular Human Skin Graft: Preclinical Assessment and In Vitro Study. Transplant Proc. 2020;52(7):2204-2207.
[20] KUO S, KIM HM, WANG Z, et al. Comparison of two decellularized dermal equivalents. J Tissue Eng Regen Med. 2018;12(4):983-990.
[21] HUANG W, CHEN Y, WANG N, et al. The Efficacy and Safety of Acellular Matrix Therapy for Diabetic Foot Ulcers: A Meta-Analysis of Randomized Clinical Trials. J Diabetes Res. 2020;2020:6245758.
[22] DASGUPTA A, ORGILL D, GALIANO RD,et al. A Novel Reticular Dermal Graft Leverages Architectural and Biological Properties to Support Wound Repair. Plast Reconstr Surg Global Open. 2016;4(10):e1065.
[23] CHO H, BLATCHLEY MR, DUH EJ, et al. Acellular and cellular approaches to improve diabetic wound healing. Advanced Drug Delivery Reviews. 2019;146:267-288.
[24] AHMEDBEYLI C, IPCI SD, CAKAR G, et al. Laterally positioned flap along with acellular dermal matrix graft in the management of maxillary localized recessions. Clin Oral Investig. 2019;23(2):595-601.
[25] KUO KC, LIN RZ, TIEN HW, et al. Bioengineering vascularized tissue constructs using an injectable cell-laden enzymatically crosslinked collagen hydrogel derived from dermal extracellular matrix. Acta Biomater. 2015;27:151-166.
[26] WOOD BC, MANTILLA-RIVAS E, GOLDRICH A, et al. Correction of Microstomia Reconstruction with the Use of Acellular Dermal Matrix for Buccal Reconstruction. J Craniofac Surg. 2019;30(3):736-738.
[27] YANG Z, WU X, CHEN C, et al. Comparison of type I tympanoplasty with acellular dermal allograft and cartilage perichondrium. Acta Oto-Laryngol. 139:10:833-836.
[28] HU Z, ZHU J, CAO X, et al. Composite Skin Grafting with Human Acellular Dermal Matrix Scaffold for Treatment of Diabetic Foot Ulcers: A Randomized Controlled Trial. J Am Coll Surg. 2016;222(6):1171-1179.
[29] CAZZELL S, VAYSER D, PHAM H, et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair Regen. 2017;25(3): 483-497.
[30] ZELEN CM, ORGILL DP, SERENA TE, et al. Human Reticular Acellular Dermal Matrix in the Healing of Chronic Diabetic Foot Ulcerations that Failed Standard Conservative Treatment: A Retrospective Crossover Study. Wounds. 2017;29(2):39-45.
[31] LEE M, JUN D, CHOI H, et al. Clinical Efficacy of Acellular Dermal Matrix Paste in Treating Diabetic Foot Ulcers. Wounds. 2020;32(1):50-56.
[32] CAZZELL S. A Randomized Controlled Trial Comparing a Human Acellular Dermal Matrix Versus Conventional Care for the Treatment of Venous Leg Ulcers. Wounds. 2019;31(3):68-74.
[33] LUTHRINGER M, MUKHERJEE T, ARGUELLO-ANGARITA M, et al. Human-derived Acellular Dermal Matrix Grafts for Treatment of Diabetic Foot Ulcers: A Systematic Review and Meta-analysis. Wounds. 2020;32(2):57-65.
[34] KIM YH, HWANG KT, KIM KH,et al. Application of acellular human dermis and skin grafts for lower extremity reconstruction. J Wound Care. 2019;28(Sup4):S12-S17.
[35] ÁLVARO-AFONSO FJ, GARCÍA-ÁLVAREZ Y, LÁZARO-MARTÍNEZ JL,et al. Advances in Dermoepidermal Skin Substitutes for Diabetic Foot Ulcers. Curr Vasc Pharmacol. 2020;18(2):182-192.
[36] TCHERO H, HERLIN C, BEKARA F, et al. Failure rates of artificial dermis products in treatment of diabetic foot ulcer: A systematic review and network meta-analysis. Wound Repair Regen. 2017;25(4):691-696.
[37] WALTERS J, CAZZELL S, PHAM H,et al. Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix Versus Conventional Care Wound Management and an Active Comparator in the Treatment of Full-Thickness Diabetic Foot Ulcers. Eplasty. 2016;16:e10.
[38] TOGNETTI L, PIANIGIANI E, IERARDI F, et al. The use of human acellular dermal matrices in advanced wound healing and surgical procedures: State of the art. Dermatol Ther. 2021;34(4):e14987.
[39] JEON H, KIM J, YEO H, et al. Treatment of diabetic foot ulcer using matriderm in comparison with a skin graft. Arch Plast Surg. 2013;40(4): 403-408.
[40] TCHANQUE-FOSSUO CN, DAHLE SE, LEV-TOV H, et al. Cellular versus acellular matrix devices in the treatment of diabetic foot ulcers: Interim results of a comparative efficacy randomized controlled trial. J Tissue Eng Regen Med. 2019;13(8):1430-1437.